STOCK TITAN
  1. Home
  2. News
  3. GOVXW

Geovax Labs Inc - GOVXW STOCK NEWS

Welcome to our dedicated news page for Geovax Labs (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on Geovax Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Geovax Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Geovax Labs's position in the market.

News
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) presented data on GEO-CM04S1, its next-generation Covid-19 vaccine candidate, at the 24th Annual World Vaccine Congress. The vaccine induces broadly specific antibody and T cell responses against SARS-CoV-2 variants, including Omicron XBB.1.5. Animal studies showed promising results in controlling disease and lung inflammation. Phase 2 clinical trials are anticipated to confirm these findings later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
covid-19
-
News
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announces Chief Scientific Officer, Mark Newman, PhD, to present data on GEO-CM04S1, the next-generation Covid-19 vaccine candidate, at the 24th Annual World Vaccine Congress. The presentation will highlight the vaccine's ability to induce broadly-specific antibody and T cell responses to combat SARS-CoV-2 variation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
conferences covid-19
-
News
GeoVax to Present at the 36th Annual Roth Conference
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announced that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference on March 18, 2024. The company will also host in-person investor meetings, providing a platform for institutional investors to engage with GeoVax leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
conferences
News
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Rhea-AI Summary
GeoVax Labs, Inc. achieves a milestone in developing a manufacturing process for Phase 3 and commercial production of MVA-based vaccines, including a next-generation Covid-19 vaccine. The company successfully transfers production to a commercial manufacturing platform, partnering with ABL Europe for cGMP manufacturing. GeoVax demonstrates progress in addressing medical needs for immunocompromised populations and enhancing manufacturing capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announced financial results and key operational achievements for 2023, focusing on progress in multiple clinical trials for their next-generation Covid-19 vaccine, GEO-CM04S1, and cancer therapy Gedeptin®. The company completed enrollment for Phase 2 trials of GEO-CM04S1, showcasing safety and efficacy against various SARS-CoV-2 strains. Results demonstrated potential protective immunity without the need for vaccine reconfiguration. Additionally, Phase 1/2 trial results for Gedeptin showed safety and tumor reduction, with plans for an expanded Phase 2 study. Operational developments included advancements in vaccine manufacturing processes and intellectual property achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
earnings
-
News
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
Rhea-AI Summary
GeoVax Labs, Inc. (GOVX) will report its 2023 financial results on February 29, 2024, after U.S. markets close. The company, a clinical-stage biotechnology firm, specializes in developing immunotherapies and vaccines for cancer and infectious diseases. A live conference call and webcast will follow the financial report for a corporate update and Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences earnings
News
GeoVax to Present at the 2024 BIO CEO & Investor Conference
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announces its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference in New York. The company will also conduct one-on-one meetings during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
GeoVax Announces Multiple Patent Issuances and Allowances
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) announces strengthening of intellectual property assets for its cancer immunotherapy program, Marburg virus, and HIV vaccines. The company received patent approvals from the Japanese Patent Office and the U.S. Patent and Trademark Office for various technologies related to immunotherapies and vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
News
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Rhea-AI Summary
GeoVax Labs, Inc. announces positive initial safety and immune response findings from its Phase 2 clinical trial for its Covid-19 vaccine, GEO-CM04S1. The trial, evaluating GEO-CM04S1 as a heterologous booster in 63 healthy adults who had previously received the Pfizer or Moderna mRNA vaccine, showed no serious adverse events and documented statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, including Delta and Omicron XBB 1.5. GEO-CM04S1 is designed to induce both antibody and T-cell responses to protect against severe disease caused by continually emerging variants of Covid-19.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
clinical trial covid-19
News
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Rhea-AI Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced a 1-for-15 reverse stock split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market. The reverse split will be effective on January 30, 2024, with the Common Stock expected to begin trading on the split-adjusted basis on the Nasdaq Stock Exchange at the market open on January 31, 2024. The total number of issued and outstanding shares of Common Stock will be reduced proportionately from 29,757,823 shares to approximately 1,983,855 shares. The reverse split will not affect the rights and privileges of the holders of shares of Common Stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.25%
Tags
stock split
Stock GOVXW logo
Geovax Labs Inc

Nasdaq:GOVXW

GOVXW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

GOVXW Stock Data

1.89M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Smyrna

About GOVXW

geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.